Follow up of Patients With Aortic Aneurysm by Dosage of Circulant Endothelial Progenitor Cells

Thoracic or Abdominal Aortic Aneurysm With no Indication for Surgical Treatment Clinical Trial

— ANOPEC 3  

Official title:

Follow up of Patients With Aortic Aneurysm by Dosage of Circulant Endothelial Progenitor Cells

Clinical Trial Details — Status: Recruiting

Administrative data

• NCT number: NCT02919709
• Other study ID #: P/2013/186
• Status: Recruiting
• Phase: N/A
• Start date: November 2013
• Est. completion date: November 2018

Study information

• Verified date: July 2018
• Source: Centre Hospitalier Universitaire de Besancon
• Contact: Andrea PERROTTI, MD
• Email: aperrotti[@]chu-besancon.fr
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

The study aims to investigate the existence of a reliable correlation between the progression of aortic diameters and blood levels of circulant endothelial progenitor cells CD34+ in patients with not surgical aortic aneurysms.

Recruitment information / eligibility

• Status: Recruiting
• Enrollment: 40
• Est. completion date: November 2018
• Est. primary completion date: November 2018
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

1. Patients aged 18 or more.

2. Patients diagnosed with a thoracic or abdominal aortic aneurysm with no indication for surgical treatment (diameters > 30 mm but < 50 mm).

3. Patients accepting to sign a specific informed consent.

Exclusion Criteria:

1. Unstable coronary artery disease.

2. Congenital heart disease.

3. Any evolving infectious syndrome or viral infection (HIV, HBV or HCV).

4. Any chronic inflammatory or autoimmune disease.

5. Prior administration of G-CSF; EPO; GM-CSF.

6. Liver failure.

7. Prior oncologic disease or ongoing cancer with a life expectancy < 1 year.

8. Dementia.

9. Pregnancy.

10. Patients aged < 18.

Related Conditions & MeSH terms

• Aneurysm
• Aortic Aneurysm
• Aortic Aneurysm, Abdominal
• Thoracic or Abdominal Aortic Aneurysm With no Indication for Surgical Treatment

Intervention

Biological:
• blood taking

Locations

Country	Name	City	State
France	CHRU de Besançon	Besançon

Sponsors (1)

Lead Sponsor	Collaborator
Centre Hospitalier Universitaire de Besancon

Country where clinical trial is conducted

France, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	progenitor cells CD34+ blood levels		At diagnosis of aneurysm
Primary	progenitor cells CD34+ blood levels		6 month after disgnosis
Primary	progenitor cells CD34+ blood levels		12 month after diagnosis
Primary	progenitor cells CD34+ blood levels		18 month after diagnosis
Primary	progenitor cells CD34+ blood levels		24 month after diagnosis